nodes	percent_of_prediction	percent_of_DWPC	metapath
Daunorubicin—ABCC6—Dactinomycin—skin cancer	0.146	0.195	CbGbCtD
Daunorubicin—ABCC1—Vemurafenib—skin cancer	0.0649	0.0866	CbGbCtD
Daunorubicin—ABCC10—Docetaxel—skin cancer	0.0576	0.077	CbGbCtD
Daunorubicin—ABCG2—Vismodegib—skin cancer	0.0549	0.0733	CbGbCtD
Daunorubicin—ABCG2—Vemurafenib—skin cancer	0.0434	0.058	CbGbCtD
Daunorubicin—ABCC1—Dactinomycin—skin cancer	0.0431	0.0576	CbGbCtD
Daunorubicin—CYP1A2—Imiquimod—skin cancer	0.0327	0.0436	CbGbCtD
Daunorubicin—CYP1B1—Docetaxel—skin cancer	0.0313	0.0418	CbGbCtD
Daunorubicin—CYP1A1—Dacarbazine—skin cancer	0.0307	0.041	CbGbCtD
Daunorubicin—ABCG2—Dactinomycin—skin cancer	0.0288	0.0385	CbGbCtD
Daunorubicin—ABCC1—Docetaxel—skin cancer	0.0223	0.0297	CbGbCtD
Daunorubicin—ABCB1—Vismodegib—skin cancer	0.0198	0.0264	CbGbCtD
Daunorubicin—ABCG2—Fluorouracil—skin cancer	0.0195	0.026	CbGbCtD
Daunorubicin—CYP1A2—Vemurafenib—skin cancer	0.0179	0.0239	CbGbCtD
Daunorubicin—CYP3A4—Imiquimod—skin cancer	0.0171	0.0229	CbGbCtD
Daunorubicin—CYP3A4—Temozolomide—skin cancer	0.0171	0.0229	CbGbCtD
Daunorubicin—ABCC2—Docetaxel—skin cancer	0.0165	0.022	CbGbCtD
Daunorubicin—ABCG2—Docetaxel—skin cancer	0.0149	0.0199	CbGbCtD
Daunorubicin—CYP1A2—Dacarbazine—skin cancer	0.0137	0.0183	CbGbCtD
Daunorubicin—CYP3A4—Vismodegib—skin cancer	0.0119	0.0158	CbGbCtD
Daunorubicin—ABCB1—Dactinomycin—skin cancer	0.0104	0.0139	CbGbCtD
Daunorubicin—CYP3A4—Vemurafenib—skin cancer	0.00938	0.0125	CbGbCtD
Daunorubicin—ABCC6—dermis—skin cancer	0.00928	0.168	CbGeAlD
Daunorubicin—CYP3A5—Docetaxel—skin cancer	0.00825	0.011	CbGbCtD
Daunorubicin—CYP1A2—Fluorouracil—skin cancer	0.00804	0.0107	CbGbCtD
Daunorubicin—ABCB1—Docetaxel—skin cancer	0.00537	0.00717	CbGbCtD
Daunorubicin—CYP3A4—Docetaxel—skin cancer	0.00322	0.0043	CbGbCtD
Daunorubicin—TOP2B—hair follicle—skin cancer	0.00253	0.0458	CbGeAlD
Daunorubicin—YWHAG—nipple—skin cancer	0.00178	0.0322	CbGeAlD
Daunorubicin—TOP2B—nipple—skin cancer	0.00171	0.031	CbGeAlD
Daunorubicin—YWHAG—Insulin-mediated glucose transport—ASIP—skin cancer	0.00156	0.125	CbGpPWpGaD
Daunorubicin—TOP2A—Sorafenib—Vismodegib—skin cancer	0.00148	0.584	CbGdCrCtD
Daunorubicin—NR5A1—lymphoid tissue—skin cancer	0.0014	0.0253	CbGeAlD
Daunorubicin—POR—nipple—skin cancer	0.00135	0.0245	CbGeAlD
Daunorubicin—NR5A1—female reproductive system—skin cancer	0.00135	0.0244	CbGeAlD
Daunorubicin—ABCC6—connective tissue—skin cancer	0.00134	0.0243	CbGeAlD
Daunorubicin—YWHAG—connective tissue—skin cancer	0.00126	0.0228	CbGeAlD
Daunorubicin—TOP2A—nipple—skin cancer	0.00126	0.0228	CbGeAlD
Daunorubicin—CYP1B1—hair follicle—skin cancer	0.00124	0.0225	CbGeAlD
Daunorubicin—CYP1A1—skin epidermis—skin cancer	0.00123	0.0223	CbGeAlD
Daunorubicin—TOP2B—connective tissue—skin cancer	0.00122	0.022	CbGeAlD
Daunorubicin—NR5A1—head—skin cancer	0.00112	0.0204	CbGeAlD
Daunorubicin—ABCC1—hair follicle—skin cancer	0.00112	0.0203	CbGeAlD
Daunorubicin—ABCC10—nipple—skin cancer	0.00107	0.0194	CbGeAlD
Daunorubicin—TOP2A—Paclitaxel—Docetaxel—skin cancer	0.00106	0.416	CbGdCrCtD
Daunorubicin—YWHAG—mammalian vulva—skin cancer	0.00104	0.0188	CbGeAlD
Daunorubicin—XDH—mammalian vulva—skin cancer	0.00101	0.0183	CbGeAlD
Daunorubicin—TOP2B—mammalian vulva—skin cancer	0.001	0.0181	CbGeAlD
Daunorubicin—YWHAG—lymphoid tissue—skin cancer	0.000922	0.0167	CbGeAlD
Daunorubicin—YWHAG—female reproductive system—skin cancer	0.00089	0.0161	CbGeAlD
Daunorubicin—TOP2B—lymphoid tissue—skin cancer	0.000889	0.0161	CbGeAlD
Daunorubicin—XDH—female reproductive system—skin cancer	0.000868	0.0157	CbGeAlD
Daunorubicin—TOP2B—female reproductive system—skin cancer	0.000857	0.0155	CbGeAlD
Daunorubicin—NR5A1—Ovarian Infertility Genes—MLH1—skin cancer	0.000822	0.0656	CbGpPWpGaD
Daunorubicin—POR—mammalian vulva—skin cancer	0.00079	0.0143	CbGeAlD
Daunorubicin—ABCC6—head—skin cancer	0.000789	0.0143	CbGeAlD
Daunorubicin—ABCC1—nipple—skin cancer	0.000759	0.0137	CbGeAlD
Daunorubicin—YWHAG—head—skin cancer	0.000743	0.0135	CbGeAlD
Daunorubicin—TOP2A—mammalian vulva—skin cancer	0.000736	0.0133	CbGeAlD
Daunorubicin—TOP2B—head—skin cancer	0.000716	0.013	CbGeAlD
Daunorubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—EXOC2—skin cancer	0.000653	0.0521	CbGpPWpGaD
Daunorubicin—ABCC10—mammalian vulva—skin cancer	0.000627	0.0113	CbGeAlD
Daunorubicin—CYP1A2—nipple—skin cancer	0.000605	0.0109	CbGeAlD
Daunorubicin—CYP1B1—connective tissue—skin cancer	0.000598	0.0108	CbGeAlD
Daunorubicin—CYP1A1—nipple—skin cancer	0.000596	0.0108	CbGeAlD
Daunorubicin—ABCC10—lymphoid tissue—skin cancer	0.000556	0.0101	CbGeAlD
Daunorubicin—CYP1B1—skin of body—skin cancer	0.00054	0.00978	CbGeAlD
Daunorubicin—ABCC10—female reproductive system—skin cancer	0.000537	0.00972	CbGeAlD
Daunorubicin—YWHAG—lymph node—skin cancer	0.00052	0.00942	CbGeAlD
Daunorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—skin cancer	0.000514	0.0411	CbGpPWpGaD
Daunorubicin—TOP2B—lymph node—skin cancer	0.000502	0.00908	CbGeAlD
Daunorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT14—skin cancer	0.000478	0.0382	CbGpPWpGaD
Daunorubicin—ABCC1—mammalian vulva—skin cancer	0.000443	0.00803	CbGeAlD
Daunorubicin—CYP1B1—lymphoid tissue—skin cancer	0.000438	0.00792	CbGeAlD
Daunorubicin—ABCC2—female reproductive system—skin cancer	0.000431	0.0078	CbGeAlD
Daunorubicin—ABCB1—blood vessel—skin cancer	0.000429	0.00776	CbGeAlD
Daunorubicin—CYP1B1—female reproductive system—skin cancer	0.000422	0.00764	CbGeAlD
Daunorubicin—NR5A1—Ovarian Infertility Genes—CDK4—skin cancer	0.000418	0.0334	CbGpPWpGaD
Daunorubicin—CYP1A1—epithelium—skin cancer	0.000402	0.00727	CbGeAlD
Daunorubicin—POR—lymph node—skin cancer	0.000396	0.00717	CbGeAlD
Daunorubicin—CYP1A1—skin of body—skin cancer	0.000382	0.00692	CbGeAlD
Daunorubicin—TOP2A—lymph node—skin cancer	0.000369	0.00668	CbGeAlD
Daunorubicin—ABCG2—mammalian vulva—skin cancer	0.000367	0.00664	CbGeAlD
Daunorubicin—YWHAG—Class I PI3K signaling events mediated by Akt—FOXO4—skin cancer	0.000363	0.029	CbGpPWpGaD
Daunorubicin—CYP1B1—head—skin cancer	0.000353	0.00638	CbGeAlD
Daunorubicin—CYP1A1—mammalian vulva—skin cancer	0.000348	0.00631	CbGeAlD
Daunorubicin—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000329	0.0262	CbGpPWpGaD
Daunorubicin—ABCC10—lymph node—skin cancer	0.000314	0.00569	CbGeAlD
Daunorubicin—CYP1A1—female reproductive system—skin cancer	0.000298	0.0054	CbGeAlD
Daunorubicin—YWHAG—FoxO family signaling—FOXO4—skin cancer	0.000278	0.0222	CbGpPWpGaD
Daunorubicin—YWHAG—Membrane Trafficking—EXOC2—skin cancer	0.000263	0.021	CbGpPWpGaD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—skin cancer	0.000257	0.0205	CbGpPWpGaD
Daunorubicin—ABCC2—lymph node—skin cancer	0.000252	0.00456	CbGeAlD
Daunorubicin—CYP1A1—head—skin cancer	0.000249	0.00451	CbGeAlD
Daunorubicin—Hot flush—Docetaxel—skin cancer	0.000247	0.00137	CcSEcCtD
Daunorubicin—Flushing—Dactinomycin—skin cancer	0.000247	0.00137	CcSEcCtD
Daunorubicin—CYP1B1—lymph node—skin cancer	0.000247	0.00447	CbGeAlD
Daunorubicin—Hypersensitivity—Vemurafenib—skin cancer	0.000247	0.00136	CcSEcCtD
Daunorubicin—Fatigue—Imiquimod—skin cancer	0.000246	0.00136	CcSEcCtD
Daunorubicin—Menopausal symptoms—Docetaxel—skin cancer	0.000245	0.00136	CcSEcCtD
Daunorubicin—Atrial fibrillation—Docetaxel—skin cancer	0.000244	0.00135	CcSEcCtD
Daunorubicin—Pain—Imiquimod—skin cancer	0.000244	0.00135	CcSEcCtD
Daunorubicin—Acute coronary syndrome—Fluorouracil—skin cancer	0.000244	0.00135	CcSEcCtD
Daunorubicin—Renal impairment—Docetaxel—skin cancer	0.000243	0.00134	CcSEcCtD
Daunorubicin—Neuropathy peripheral—Fluorouracil—skin cancer	0.000242	0.00134	CcSEcCtD
Daunorubicin—Myocardial infarction—Fluorouracil—skin cancer	0.000242	0.00134	CcSEcCtD
Daunorubicin—Stomatitis—Fluorouracil—skin cancer	0.000241	0.00133	CcSEcCtD
Daunorubicin—Conjunctivitis—Fluorouracil—skin cancer	0.00024	0.00133	CcSEcCtD
Daunorubicin—Asthenia—Vemurafenib—skin cancer	0.00024	0.00133	CcSEcCtD
Daunorubicin—Hallucination—Temozolomide—skin cancer	0.00024	0.00132	CcSEcCtD
Daunorubicin—Chills—Dactinomycin—skin cancer	0.000239	0.00132	CcSEcCtD
Daunorubicin—Cardiac failure—Docetaxel—skin cancer	0.000237	0.00131	CcSEcCtD
Daunorubicin—Pruritus—Vemurafenib—skin cancer	0.000237	0.00131	CcSEcCtD
Daunorubicin—Alopecia—Dactinomycin—skin cancer	0.000235	0.0013	CcSEcCtD
Daunorubicin—Feeling abnormal—Imiquimod—skin cancer	0.000235	0.0013	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Imiquimod—skin cancer	0.000233	0.00129	CcSEcCtD
Daunorubicin—Visual impairment—Temozolomide—skin cancer	0.000232	0.00128	CcSEcCtD
Daunorubicin—Sinusitis—Fluorouracil—skin cancer	0.000232	0.00128	CcSEcCtD
Daunorubicin—Erythema—Dactinomycin—skin cancer	0.000232	0.00128	CcSEcCtD
Daunorubicin—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000231	0.00128	CcSEcCtD
Daunorubicin—Ill-defined disorder—Bleomycin—skin cancer	0.000231	0.00127	CcSEcCtD
Daunorubicin—Anaemia—Bleomycin—skin cancer	0.00023	0.00127	CcSEcCtD
Daunorubicin—Diarrhoea—Vemurafenib—skin cancer	0.000229	0.00127	CcSEcCtD
Daunorubicin—Urticaria—Imiquimod—skin cancer	0.000227	0.00125	CcSEcCtD
Daunorubicin—Abdominal pain—Imiquimod—skin cancer	0.000226	0.00125	CcSEcCtD
Daunorubicin—Body temperature increased—Imiquimod—skin cancer	0.000226	0.00125	CcSEcCtD
Daunorubicin—Tinnitus—Temozolomide—skin cancer	0.000225	0.00124	CcSEcCtD
Daunorubicin—Malaise—Bleomycin—skin cancer	0.000224	0.00124	CcSEcCtD
Daunorubicin—Flushing—Temozolomide—skin cancer	0.000223	0.00124	CcSEcCtD
Daunorubicin—Cardiac disorder—Temozolomide—skin cancer	0.000223	0.00124	CcSEcCtD
Daunorubicin—Leukopenia—Bleomycin—skin cancer	0.000222	0.00123	CcSEcCtD
Daunorubicin—Rhinitis—Fluorouracil—skin cancer	0.000222	0.00123	CcSEcCtD
Daunorubicin—ABCC1—lymph node—skin cancer	0.000222	0.00402	CbGeAlD
Daunorubicin—Dizziness—Vemurafenib—skin cancer	0.000221	0.00122	CcSEcCtD
Daunorubicin—CYP3A4—female reproductive system—skin cancer	0.000219	0.00396	CbGeAlD
Daunorubicin—Ataxia—Docetaxel—skin cancer	0.000218	0.0012	CcSEcCtD
Daunorubicin—Cough—Bleomycin—skin cancer	0.000217	0.0012	CcSEcCtD
Daunorubicin—Chills—Temozolomide—skin cancer	0.000216	0.00119	CcSEcCtD
Daunorubicin—Dehydration—Docetaxel—skin cancer	0.000215	0.00119	CcSEcCtD
Daunorubicin—Ill-defined disorder—Dactinomycin—skin cancer	0.000215	0.00119	CcSEcCtD
Daunorubicin—Anaemia—Dactinomycin—skin cancer	0.000214	0.00118	CcSEcCtD
Daunorubicin—Vomiting—Vemurafenib—skin cancer	0.000213	0.00118	CcSEcCtD
Daunorubicin—Alopecia—Temozolomide—skin cancer	0.000213	0.00118	CcSEcCtD
Daunorubicin—Dry skin—Docetaxel—skin cancer	0.000212	0.00117	CcSEcCtD
Daunorubicin—Myalgia—Bleomycin—skin cancer	0.000212	0.00117	CcSEcCtD
Daunorubicin—Chest pain—Bleomycin—skin cancer	0.000212	0.00117	CcSEcCtD
Daunorubicin—Rash—Vemurafenib—skin cancer	0.000211	0.00117	CcSEcCtD
Daunorubicin—Dermatitis—Vemurafenib—skin cancer	0.000211	0.00117	CcSEcCtD
Daunorubicin—Hypersensitivity—Imiquimod—skin cancer	0.00021	0.00116	CcSEcCtD
Daunorubicin—Headache—Vemurafenib—skin cancer	0.00021	0.00116	CcSEcCtD
Daunorubicin—Erythema—Temozolomide—skin cancer	0.00021	0.00116	CcSEcCtD
Daunorubicin—Discomfort—Bleomycin—skin cancer	0.000209	0.00116	CcSEcCtD
Daunorubicin—Malaise—Dactinomycin—skin cancer	0.000209	0.00116	CcSEcCtD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000209	0.0167	CbGpPWpGaD
Daunorubicin—ABCB1—epithelium—skin cancer	0.000209	0.00378	CbGeAlD
Daunorubicin—Leukopenia—Dactinomycin—skin cancer	0.000207	0.00115	CcSEcCtD
Daunorubicin—Dysgeusia—Temozolomide—skin cancer	0.000205	0.00113	CcSEcCtD
Daunorubicin—Asthenia—Imiquimod—skin cancer	0.000205	0.00113	CcSEcCtD
Daunorubicin—Confusional state—Bleomycin—skin cancer	0.000204	0.00113	CcSEcCtD
Daunorubicin—Anaphylactic shock—Bleomycin—skin cancer	0.000203	0.00112	CcSEcCtD
Daunorubicin—Oedema—Bleomycin—skin cancer	0.000203	0.00112	CcSEcCtD
Daunorubicin—Back pain—Temozolomide—skin cancer	0.000203	0.00112	CcSEcCtD
Daunorubicin—Pruritus—Imiquimod—skin cancer	0.000202	0.00112	CcSEcCtD
Daunorubicin—Infection—Bleomycin—skin cancer	0.000201	0.00111	CcSEcCtD
Daunorubicin—Dysphagia—Docetaxel—skin cancer	0.0002	0.00111	CcSEcCtD
Daunorubicin—Nausea—Vemurafenib—skin cancer	0.000199	0.0011	CcSEcCtD
Daunorubicin—Thrombocytopenia—Bleomycin—skin cancer	0.000199	0.0011	CcSEcCtD
Daunorubicin—Arrhythmia—Fluorouracil—skin cancer	0.000198	0.0011	CcSEcCtD
Daunorubicin—Myalgia—Dactinomycin—skin cancer	0.000197	0.00109	CcSEcCtD
Daunorubicin—Tremor—Temozolomide—skin cancer	0.000196	0.00109	CcSEcCtD
Daunorubicin—Alopecia—Fluorouracil—skin cancer	0.000196	0.00108	CcSEcCtD
Daunorubicin—Diarrhoea—Imiquimod—skin cancer	0.000195	0.00108	CcSEcCtD
Daunorubicin—Discomfort—Dactinomycin—skin cancer	0.000195	0.00108	CcSEcCtD
Daunorubicin—Angina pectoris—Docetaxel—skin cancer	0.000195	0.00108	CcSEcCtD
Daunorubicin—Ill-defined disorder—Temozolomide—skin cancer	0.000194	0.00108	CcSEcCtD
Daunorubicin—Anaemia—Temozolomide—skin cancer	0.000194	0.00107	CcSEcCtD
Daunorubicin—Anorexia—Bleomycin—skin cancer	0.000193	0.00107	CcSEcCtD
Daunorubicin—Erythema—Fluorouracil—skin cancer	0.000193	0.00107	CcSEcCtD
Daunorubicin—Agitation—Temozolomide—skin cancer	0.000193	0.00106	CcSEcCtD
Daunorubicin—Pancytopenia—Docetaxel—skin cancer	0.00019	0.00105	CcSEcCtD
Daunorubicin—Oedema—Dactinomycin—skin cancer	0.000189	0.00105	CcSEcCtD
Daunorubicin—Malaise—Temozolomide—skin cancer	0.000189	0.00105	CcSEcCtD
Daunorubicin—Dizziness—Imiquimod—skin cancer	0.000189	0.00104	CcSEcCtD
Daunorubicin—Infection—Dactinomycin—skin cancer	0.000188	0.00104	CcSEcCtD
Daunorubicin—Leukopenia—Temozolomide—skin cancer	0.000188	0.00104	CcSEcCtD
Daunorubicin—Neutropenia—Docetaxel—skin cancer	0.000187	0.00103	CcSEcCtD
Daunorubicin—Palpitations—Temozolomide—skin cancer	0.000185	0.00102	CcSEcCtD
Daunorubicin—Thrombocytopenia—Dactinomycin—skin cancer	0.000185	0.00102	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000185	0.00102	CcSEcCtD
Daunorubicin—ABCG2—lymph node—skin cancer	0.000184	0.00333	CbGeAlD
Daunorubicin—Cough—Temozolomide—skin cancer	0.000183	0.00101	CcSEcCtD
Daunorubicin—Convulsion—Temozolomide—skin cancer	0.000182	0.001	CcSEcCtD
Daunorubicin—Vomiting—Imiquimod—skin cancer	0.000182	0.001	CcSEcCtD
Daunorubicin—Hypertension—Temozolomide—skin cancer	0.000181	0.001	CcSEcCtD
Daunorubicin—ABCB1—mammalian vulva—skin cancer	0.000181	0.00328	CbGeAlD
Daunorubicin—Dyspnoea—Bleomycin—skin cancer	0.000181	0.001	CcSEcCtD
Daunorubicin—Anorexia—Dactinomycin—skin cancer	0.00018	0.000997	CcSEcCtD
Daunorubicin—Rash—Imiquimod—skin cancer	0.00018	0.000995	CcSEcCtD
Daunorubicin—Dermatitis—Imiquimod—skin cancer	0.00018	0.000994	CcSEcCtD
Daunorubicin—Headache—Imiquimod—skin cancer	0.000179	0.000989	CcSEcCtD
Daunorubicin—Anaemia—Fluorouracil—skin cancer	0.000179	0.000987	CcSEcCtD
Daunorubicin—Myalgia—Temozolomide—skin cancer	0.000178	0.000987	CcSEcCtD
Daunorubicin—Arthralgia—Temozolomide—skin cancer	0.000178	0.000987	CcSEcCtD
Daunorubicin—Anxiety—Temozolomide—skin cancer	0.000178	0.000983	CcSEcCtD
Daunorubicin—Discomfort—Temozolomide—skin cancer	0.000176	0.000975	CcSEcCtD
Daunorubicin—Decreased appetite—Bleomycin—skin cancer	0.000176	0.000975	CcSEcCtD
Daunorubicin—Acute coronary syndrome—Docetaxel—skin cancer	0.000176	0.000972	CcSEcCtD
Daunorubicin—Renal failure—Docetaxel—skin cancer	0.000175	0.000969	CcSEcCtD
Daunorubicin—Myocardial infarction—Docetaxel—skin cancer	0.000175	0.000967	CcSEcCtD
Daunorubicin—Neuropathy peripheral—Docetaxel—skin cancer	0.000175	0.000967	CcSEcCtD
Daunorubicin—Dry mouth—Temozolomide—skin cancer	0.000175	0.000965	CcSEcCtD
Daunorubicin—CYP1A1—lymph node—skin cancer	0.000175	0.00316	CbGeAlD
Daunorubicin—Stomatitis—Docetaxel—skin cancer	0.000174	0.000961	CcSEcCtD
Daunorubicin—Pain—Bleomycin—skin cancer	0.000173	0.000959	CcSEcCtD
Daunorubicin—Conjunctivitis—Docetaxel—skin cancer	0.000173	0.000959	CcSEcCtD
Daunorubicin—Leukopenia—Fluorouracil—skin cancer	0.000173	0.000956	CcSEcCtD
Daunorubicin—Confusional state—Temozolomide—skin cancer	0.000172	0.000954	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000172	0.000953	CcSEcCtD
Daunorubicin—Anaphylactic shock—Temozolomide—skin cancer	0.000171	0.000946	CcSEcCtD
Daunorubicin—Oedema—Temozolomide—skin cancer	0.000171	0.000946	CcSEcCtD
Daunorubicin—Infection—Temozolomide—skin cancer	0.00017	0.00094	CcSEcCtD
Daunorubicin—Nausea—Imiquimod—skin cancer	0.00017	0.000937	CcSEcCtD
Daunorubicin—Thrombocytopenia—Temozolomide—skin cancer	0.000167	0.000926	CcSEcCtD
Daunorubicin—Convulsion—Fluorouracil—skin cancer	0.000167	0.000925	CcSEcCtD
Daunorubicin—Feeling abnormal—Bleomycin—skin cancer	0.000167	0.000924	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—SCN10A—skin cancer	0.000166	0.0133	CbGpPWpGaD
Daunorubicin—Hyperhidrosis—Temozolomide—skin cancer	0.000165	0.000914	CcSEcCtD
Daunorubicin—Chest pain—Fluorouracil—skin cancer	0.000164	0.000909	CcSEcCtD
Daunorubicin—Myalgia—Fluorouracil—skin cancer	0.000164	0.000909	CcSEcCtD
Daunorubicin—Decreased appetite—Dactinomycin—skin cancer	0.000164	0.000909	CcSEcCtD
Daunorubicin—Fatigue—Dactinomycin—skin cancer	0.000163	0.000902	CcSEcCtD
Daunorubicin—Anorexia—Temozolomide—skin cancer	0.000163	0.000902	CcSEcCtD
Daunorubicin—Discomfort—Fluorouracil—skin cancer	0.000162	0.000898	CcSEcCtD
Daunorubicin—Pain—Dactinomycin—skin cancer	0.000162	0.000894	CcSEcCtD
Daunorubicin—Urticaria—Bleomycin—skin cancer	0.000161	0.000891	CcSEcCtD
Daunorubicin—ABCB1—lymphoid tissue—skin cancer	0.000161	0.00291	CbGeAlD
Daunorubicin—Rhinitis—Docetaxel—skin cancer	0.000161	0.000888	CcSEcCtD
Daunorubicin—Body temperature increased—Bleomycin—skin cancer	0.00016	0.000886	CcSEcCtD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—RASA1—skin cancer	0.00016	0.0128	CbGpPWpGaD
Daunorubicin—Confusional state—Fluorouracil—skin cancer	0.000159	0.000879	CcSEcCtD
Daunorubicin—Anaphylactic shock—Fluorouracil—skin cancer	0.000158	0.000871	CcSEcCtD
Daunorubicin—Oedema—Fluorouracil—skin cancer	0.000158	0.000871	CcSEcCtD
Daunorubicin—Infection—Fluorouracil—skin cancer	0.000157	0.000866	CcSEcCtD
Daunorubicin—Feeling abnormal—Dactinomycin—skin cancer	0.000156	0.000862	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000156	0.000862	CcSEcCtD
Daunorubicin—ABCB1—female reproductive system—skin cancer	0.000155	0.00281	CbGeAlD
Daunorubicin—Insomnia—Temozolomide—skin cancer	0.000155	0.000855	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Dactinomycin—skin cancer	0.000155	0.000855	CcSEcCtD
Daunorubicin—Thrombocytopenia—Fluorouracil—skin cancer	0.000154	0.000853	CcSEcCtD
Daunorubicin—Visual impairment—Docetaxel—skin cancer	0.000154	0.000853	CcSEcCtD
Daunorubicin—Tachycardia—Fluorouracil—skin cancer	0.000154	0.000851	CcSEcCtD
Daunorubicin—Dyspnoea—Temozolomide—skin cancer	0.000153	0.000843	CcSEcCtD
Daunorubicin—Somnolence—Temozolomide—skin cancer	0.000152	0.000841	CcSEcCtD
Daunorubicin—Anorexia—Fluorouracil—skin cancer	0.00015	0.000831	CcSEcCtD
Daunorubicin—Abdominal pain—Dactinomycin—skin cancer	0.00015	0.000827	CcSEcCtD
Daunorubicin—Body temperature increased—Dactinomycin—skin cancer	0.00015	0.000827	CcSEcCtD
Daunorubicin—Hypersensitivity—Bleomycin—skin cancer	0.000149	0.000826	CcSEcCtD
Daunorubicin—Decreased appetite—Temozolomide—skin cancer	0.000149	0.000822	CcSEcCtD
Daunorubicin—Cardiac disorder—Docetaxel—skin cancer	0.000149	0.000822	CcSEcCtD
Daunorubicin—Flushing—Docetaxel—skin cancer	0.000149	0.000822	CcSEcCtD
Daunorubicin—Fatigue—Temozolomide—skin cancer	0.000147	0.000815	CcSEcCtD
Daunorubicin—Pain—Temozolomide—skin cancer	0.000146	0.000809	CcSEcCtD
Daunorubicin—Constipation—Temozolomide—skin cancer	0.000146	0.000809	CcSEcCtD
Daunorubicin—Asthenia—Bleomycin—skin cancer	0.000146	0.000804	CcSEcCtD
Daunorubicin—ABCC6—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000144	0.0115	CbGpPWpGaD
Daunorubicin—Chills—Docetaxel—skin cancer	0.000144	0.000794	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000144	0.000794	CcSEcCtD
Daunorubicin—Pruritus—Bleomycin—skin cancer	0.000143	0.000793	CcSEcCtD
Daunorubicin—Arrhythmia—Docetaxel—skin cancer	0.000143	0.000791	CcSEcCtD
Daunorubicin—Insomnia—Fluorouracil—skin cancer	0.000143	0.000788	CcSEcCtD
Daunorubicin—Alopecia—Docetaxel—skin cancer	0.000142	0.000782	CcSEcCtD
Daunorubicin—Feeling abnormal—Temozolomide—skin cancer	0.000141	0.000779	CcSEcCtD
Daunorubicin—Dyspnoea—Fluorouracil—skin cancer	0.000141	0.000777	CcSEcCtD
Daunorubicin—Somnolence—Fluorouracil—skin cancer	0.00014	0.000775	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Temozolomide—skin cancer	0.00014	0.000773	CcSEcCtD
Daunorubicin—Erythema—Docetaxel—skin cancer	0.000139	0.000771	CcSEcCtD
Daunorubicin—Hypersensitivity—Dactinomycin—skin cancer	0.000139	0.00077	CcSEcCtD
Daunorubicin—Decreased appetite—Fluorouracil—skin cancer	0.000137	0.000758	CcSEcCtD
Daunorubicin—Dysgeusia—Docetaxel—skin cancer	0.000137	0.000755	CcSEcCtD
Daunorubicin—Urticaria—Temozolomide—skin cancer	0.000136	0.000751	CcSEcCtD
Daunorubicin—Asthenia—Dactinomycin—skin cancer	0.000136	0.00075	CcSEcCtD
Daunorubicin—Abdominal pain—Temozolomide—skin cancer	0.000135	0.000748	CcSEcCtD
Daunorubicin—Body temperature increased—Temozolomide—skin cancer	0.000135	0.000748	CcSEcCtD
Daunorubicin—Back pain—Docetaxel—skin cancer	0.000135	0.000745	CcSEcCtD
Daunorubicin—Pain—Fluorouracil—skin cancer	0.000135	0.000745	CcSEcCtD
Daunorubicin—TOP2A—Circadian rythm related genes—NKX2-1—skin cancer	0.000133	0.0106	CbGpPWpGaD
Daunorubicin—Feeling abnormal—Fluorouracil—skin cancer	0.00013	0.000718	CcSEcCtD
Daunorubicin—ABCB1—head—skin cancer	0.000129	0.00234	CbGeAlD
Daunorubicin—Diarrhoea—Dactinomycin—skin cancer	0.000129	0.000715	CcSEcCtD
Daunorubicin—Vomiting—Bleomycin—skin cancer	0.000129	0.000713	CcSEcCtD
Daunorubicin—Anaemia—Docetaxel—skin cancer	0.000129	0.000712	CcSEcCtD
Daunorubicin—Rash—Bleomycin—skin cancer	0.000128	0.000707	CcSEcCtD
Daunorubicin—Dermatitis—Bleomycin—skin cancer	0.000128	0.000706	CcSEcCtD
Daunorubicin—Hypersensitivity—Temozolomide—skin cancer	0.000126	0.000697	CcSEcCtD
Daunorubicin—ABCC10—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000126	0.01	CbGpPWpGaD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—skin cancer	0.000125	0.01	CbGpPWpGaD
Daunorubicin—Urticaria—Fluorouracil—skin cancer	0.000125	0.000692	CcSEcCtD
Daunorubicin—Syncope—Docetaxel—skin cancer	0.000125	0.000691	CcSEcCtD
Daunorubicin—Leukopenia—Docetaxel—skin cancer	0.000125	0.00069	CcSEcCtD
Daunorubicin—Body temperature increased—Fluorouracil—skin cancer	0.000125	0.000689	CcSEcCtD
Daunorubicin—Palpitations—Docetaxel—skin cancer	0.000123	0.000681	CcSEcCtD
Daunorubicin—Asthenia—Temozolomide—skin cancer	0.000123	0.000679	CcSEcCtD
Daunorubicin—ABCC1—S1P1 pathway—PTGS2—skin cancer	0.000123	0.00978	CbGpPWpGaD
Daunorubicin—Loss of consciousness—Docetaxel—skin cancer	0.000123	0.000677	CcSEcCtD
Daunorubicin—Cough—Docetaxel—skin cancer	0.000122	0.000673	CcSEcCtD
Daunorubicin—Pruritus—Temozolomide—skin cancer	0.000121	0.000669	CcSEcCtD
Daunorubicin—YWHAG—Activation of BH3-only proteins—TP53—skin cancer	0.000121	0.00966	CbGpPWpGaD
Daunorubicin—Convulsion—Docetaxel—skin cancer	0.000121	0.000668	CcSEcCtD
Daunorubicin—Nausea—Bleomycin—skin cancer	0.00012	0.000666	CcSEcCtD
Daunorubicin—Hypertension—Docetaxel—skin cancer	0.00012	0.000665	CcSEcCtD
Daunorubicin—Vomiting—Dactinomycin—skin cancer	0.00012	0.000665	CcSEcCtD
Daunorubicin—Rash—Dactinomycin—skin cancer	0.000119	0.000659	CcSEcCtD
Daunorubicin—Chest pain—Docetaxel—skin cancer	0.000119	0.000656	CcSEcCtD
Daunorubicin—Arthralgia—Docetaxel—skin cancer	0.000119	0.000656	CcSEcCtD
Daunorubicin—Myalgia—Docetaxel—skin cancer	0.000119	0.000656	CcSEcCtD
Daunorubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—NRAS—skin cancer	0.000118	0.00943	CbGpPWpGaD
Daunorubicin—Diarrhoea—Temozolomide—skin cancer	0.000117	0.000647	CcSEcCtD
Daunorubicin—Hypersensitivity—Fluorouracil—skin cancer	0.000116	0.000642	CcSEcCtD
Daunorubicin—Dry mouth—Docetaxel—skin cancer	0.000116	0.000642	CcSEcCtD
Daunorubicin—YWHAG—mTOR signaling pathway—BRAF—skin cancer	0.000116	0.00924	CbGpPWpGaD
Daunorubicin—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000116	0.00923	CbGpPWpGaD
Daunorubicin—Confusional state—Docetaxel—skin cancer	0.000115	0.000634	CcSEcCtD
Daunorubicin—Anaphylactic shock—Docetaxel—skin cancer	0.000114	0.000629	CcSEcCtD
Daunorubicin—Oedema—Docetaxel—skin cancer	0.000114	0.000629	CcSEcCtD
Daunorubicin—Dizziness—Temozolomide—skin cancer	0.000113	0.000625	CcSEcCtD
Daunorubicin—Infection—Docetaxel—skin cancer	0.000113	0.000625	CcSEcCtD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000113	0.00901	CbGpPWpGaD
Daunorubicin—Nausea—Dactinomycin—skin cancer	0.000112	0.000621	CcSEcCtD
Daunorubicin—Shock—Docetaxel—skin cancer	0.000112	0.000619	CcSEcCtD
Daunorubicin—Pruritus—Fluorouracil—skin cancer	0.000112	0.000617	CcSEcCtD
Daunorubicin—Thrombocytopenia—Docetaxel—skin cancer	0.000111	0.000616	CcSEcCtD
Daunorubicin—Tachycardia—Docetaxel—skin cancer	0.000111	0.000614	CcSEcCtD
Daunorubicin—Vomiting—Temozolomide—skin cancer	0.000109	0.000601	CcSEcCtD
Daunorubicin—Anorexia—Docetaxel—skin cancer	0.000108	0.0006	CcSEcCtD
Daunorubicin—Rash—Temozolomide—skin cancer	0.000108	0.000596	CcSEcCtD
Daunorubicin—Diarrhoea—Fluorouracil—skin cancer	0.000108	0.000596	CcSEcCtD
Daunorubicin—Dermatitis—Temozolomide—skin cancer	0.000108	0.000596	CcSEcCtD
Daunorubicin—Headache—Temozolomide—skin cancer	0.000107	0.000593	CcSEcCtD
Daunorubicin—Dizziness—Fluorouracil—skin cancer	0.000104	0.000576	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000104	0.000573	CcSEcCtD
Daunorubicin—Insomnia—Docetaxel—skin cancer	0.000103	0.000569	CcSEcCtD
Daunorubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—KRAS—skin cancer	0.000102	0.00812	CbGpPWpGaD
Daunorubicin—Nausea—Temozolomide—skin cancer	0.000102	0.000562	CcSEcCtD
Daunorubicin—Dyspnoea—Docetaxel—skin cancer	0.000101	0.000561	CcSEcCtD
Daunorubicin—Somnolence—Docetaxel—skin cancer	0.000101	0.000559	CcSEcCtD
Daunorubicin—Vomiting—Fluorouracil—skin cancer	0.0001	0.000554	CcSEcCtD
Daunorubicin—Rash—Fluorouracil—skin cancer	9.94e-05	0.000549	CcSEcCtD
Daunorubicin—Dermatitis—Fluorouracil—skin cancer	9.93e-05	0.000549	CcSEcCtD
Daunorubicin—Decreased appetite—Docetaxel—skin cancer	9.89e-05	0.000547	CcSEcCtD
Daunorubicin—Headache—Fluorouracil—skin cancer	9.87e-05	0.000546	CcSEcCtD
Daunorubicin—Fatigue—Docetaxel—skin cancer	9.81e-05	0.000542	CcSEcCtD
Daunorubicin—Pain—Docetaxel—skin cancer	9.73e-05	0.000538	CcSEcCtD
Daunorubicin—Constipation—Docetaxel—skin cancer	9.73e-05	0.000538	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—RASA1—skin cancer	9.54e-05	0.00762	CbGpPWpGaD
Daunorubicin—CYP1A1—PPARA activates gene expression—PLIN2—skin cancer	9.39e-05	0.00749	CbGpPWpGaD
Daunorubicin—Feeling abnormal—Docetaxel—skin cancer	9.37e-05	0.000518	CcSEcCtD
Daunorubicin—Nausea—Fluorouracil—skin cancer	9.36e-05	0.000518	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Docetaxel—skin cancer	9.3e-05	0.000514	CcSEcCtD
Daunorubicin—YWHAG—Cell Cycle—CDK4—skin cancer	9.23e-05	0.00737	CbGpPWpGaD
Daunorubicin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PLIN2—skin cancer	9.19e-05	0.00733	CbGpPWpGaD
Daunorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—skin cancer	9.17e-05	0.00732	CbGpPWpGaD
Daunorubicin—ABCB1—lymph node—skin cancer	9.07e-05	0.00164	CbGeAlD
Daunorubicin—Abdominal pain—Docetaxel—skin cancer	8.99e-05	0.000497	CcSEcCtD
Daunorubicin—Body temperature increased—Docetaxel—skin cancer	8.99e-05	0.000497	CcSEcCtD
Daunorubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—skin cancer	8.65e-05	0.00691	CbGpPWpGaD
Daunorubicin—YWHAG—Trk receptor signaling mediated by PI3K and PLC-gamma—HRAS—skin cancer	8.64e-05	0.0069	CbGpPWpGaD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—skin cancer	8.57e-05	0.00684	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Docetaxel—skin cancer	8.38e-05	0.000463	CcSEcCtD
Daunorubicin—Asthenia—Docetaxel—skin cancer	8.16e-05	0.000451	CcSEcCtD
Daunorubicin—Pruritus—Docetaxel—skin cancer	8.05e-05	0.000445	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	8.02e-05	0.0064	CbGpPWpGaD
Daunorubicin—YWHAG—ErbB1 downstream signaling—BRAF—skin cancer	7.98e-05	0.00637	CbGpPWpGaD
Daunorubicin—YWHAG—LKB1 signaling events—TP53—skin cancer	7.84e-05	0.00626	CbGpPWpGaD
Daunorubicin—Diarrhoea—Docetaxel—skin cancer	7.78e-05	0.00043	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	7.61e-05	0.00607	CbGpPWpGaD
Daunorubicin—Dizziness—Docetaxel—skin cancer	7.52e-05	0.000416	CcSEcCtD
Daunorubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	7.33e-05	0.00585	CbGpPWpGaD
Daunorubicin—YWHAG—mTOR signaling pathway—NRAS—skin cancer	7.27e-05	0.00581	CbGpPWpGaD
Daunorubicin—Vomiting—Docetaxel—skin cancer	7.23e-05	0.0004	CcSEcCtD
Daunorubicin—YWHAG—a6b1 and a6b4 Integrin signaling—HRAS—skin cancer	7.23e-05	0.00577	CbGpPWpGaD
Daunorubicin—Rash—Docetaxel—skin cancer	7.17e-05	0.000397	CcSEcCtD
Daunorubicin—Dermatitis—Docetaxel—skin cancer	7.17e-05	0.000396	CcSEcCtD
Daunorubicin—Headache—Docetaxel—skin cancer	7.13e-05	0.000394	CcSEcCtD
Daunorubicin—TOP2A—Gastric Cancer Network 2—TP53—skin cancer	7.12e-05	0.00569	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—CDKN2A—skin cancer	7.06e-05	0.00563	CbGpPWpGaD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—BRAF—skin cancer	6.94e-05	0.00554	CbGpPWpGaD
Daunorubicin—Nausea—Docetaxel—skin cancer	6.76e-05	0.000374	CcSEcCtD
Daunorubicin—SLC22A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	6.54e-05	0.00522	CbGpPWpGaD
Daunorubicin—XDH—Selenium Micronutrient Network—PTGS2—skin cancer	6.49e-05	0.00518	CbGpPWpGaD
Daunorubicin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	6.33e-05	0.00505	CbGpPWpGaD
Daunorubicin—YWHAG—mTOR signaling pathway—KRAS—skin cancer	6.26e-05	0.005	CbGpPWpGaD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	6.23e-05	0.00497	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	5.84e-05	0.00466	CbGpPWpGaD
Daunorubicin—ABCC1—Arachidonic acid metabolism—PTGS2—skin cancer	5.65e-05	0.00451	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	5.63e-05	0.0045	CbGpPWpGaD
Daunorubicin—CYP1B1—Arachidonic acid metabolism—PTGS2—skin cancer	5.47e-05	0.00436	CbGpPWpGaD
Daunorubicin—YWHAG—mTOR signaling pathway—HRAS—skin cancer	5.32e-05	0.00425	CbGpPWpGaD
Daunorubicin—TOP2A—Mitotic G1-G1/S phases—CDK4—skin cancer	5.16e-05	0.00412	CbGpPWpGaD
Daunorubicin—YWHAG—ErbB1 downstream signaling—NRAS—skin cancer	5.02e-05	0.004	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—MLH1—skin cancer	4.76e-05	0.0038	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—CDK4—skin cancer	4.68e-05	0.00373	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	4.55e-05	0.00363	CbGpPWpGaD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—NRAS—skin cancer	4.36e-05	0.00348	CbGpPWpGaD
Daunorubicin—YWHAG—ErbB1 downstream signaling—KRAS—skin cancer	4.32e-05	0.00345	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.23e-05	0.00338	CbGpPWpGaD
Daunorubicin—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	4.13e-05	0.00329	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	4.09e-05	0.00327	CbGpPWpGaD
Daunorubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—skin cancer	3.94e-05	0.00315	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—TP53—skin cancer	3.93e-05	0.00314	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	3.91e-05	0.00312	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	3.91e-05	0.00312	CbGpPWpGaD
Daunorubicin—ABCC2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.86e-05	0.00308	CbGpPWpGaD
Daunorubicin—ABCC1—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.81e-05	0.00305	CbGpPWpGaD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—KRAS—skin cancer	3.76e-05	0.003	CbGpPWpGaD
Daunorubicin—TOP2A—Circadian rythm related genes—CDK4—skin cancer	3.75e-05	0.003	CbGpPWpGaD
Daunorubicin—YWHAG—ErbB1 downstream signaling—HRAS—skin cancer	3.67e-05	0.00293	CbGpPWpGaD
Daunorubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	3.63e-05	0.0029	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	3.6e-05	0.00287	CbGpPWpGaD
Daunorubicin—XDH—Selenium Micronutrient Network—IL6—skin cancer	3.54e-05	0.00282	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—PLIN2—skin cancer	3.4e-05	0.00272	CbGpPWpGaD
Daunorubicin—CYP1A1—Arachidonic acid metabolism—PTGS2—skin cancer	3.37e-05	0.00269	CbGpPWpGaD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	3.37e-05	0.00269	CbGpPWpGaD
Daunorubicin—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.36e-05	0.00268	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—MLH1—skin cancer	3.33e-05	0.00266	CbGpPWpGaD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	3.33e-05	0.00265	CbGpPWpGaD
Daunorubicin—SLC22A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.32e-05	0.00265	CbGpPWpGaD
Daunorubicin—YWHAG—PDGFR-beta signaling pathway—HRAS—skin cancer	3.19e-05	0.00255	CbGpPWpGaD
Daunorubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—skin cancer	3.12e-05	0.00249	CbGpPWpGaD
Daunorubicin—NR5A1—Gene Expression—ERCC2—skin cancer	2.85e-05	0.00228	CbGpPWpGaD
Daunorubicin—YWHAG—Apoptosis—TP53—skin cancer	2.81e-05	0.00224	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	2.8e-05	0.00223	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.79e-05	0.00223	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—CSPG4—skin cancer	2.74e-05	0.00219	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—CDK4—skin cancer	2.71e-05	0.00216	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—TERT—skin cancer	2.7e-05	0.00216	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.64e-05	0.00211	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—NRAS—skin cancer	2.6e-05	0.00208	CbGpPWpGaD
Daunorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—skin cancer	2.57e-05	0.00205	CbGpPWpGaD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—IL6—skin cancer	2.56e-05	0.00204	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.52e-05	0.00201	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—PLIN2—skin cancer	2.51e-05	0.002	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.5e-05	0.002	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—CDK4—skin cancer	2.42e-05	0.00193	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.41e-05	0.00192	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	2.29e-05	0.00183	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—KRAS—skin cancer	2.24e-05	0.00179	CbGpPWpGaD
Daunorubicin—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	2.15e-05	0.00171	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.07e-05	0.00165	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	2.05e-05	0.00163	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—CSPG4—skin cancer	2.02e-05	0.00161	CbGpPWpGaD
Daunorubicin—SLC22A2—Transmission across Chemical Synapses—BRAF—skin cancer	2.01e-05	0.0016	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—HRAS—skin cancer	1.9e-05	0.00152	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—CDK4—skin cancer	1.89e-05	0.00151	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—TERT—skin cancer	1.89e-05	0.00151	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—PLIN2—skin cancer	1.88e-05	0.0015	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.87e-05	0.00149	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—ENO2—skin cancer	1.86e-05	0.00149	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—CDKN2A—skin cancer	1.85e-05	0.00148	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—PLIN2—skin cancer	1.82e-05	0.00146	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—IL6—skin cancer	1.82e-05	0.00145	CbGpPWpGaD
Daunorubicin—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.81e-05	0.00145	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—CSPG4—skin cancer	1.81e-05	0.00145	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	1.78e-05	0.00142	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—CDK4—skin cancer	1.69e-05	0.00135	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.66e-05	0.00133	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—PLIN2—skin cancer	1.66e-05	0.00132	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—PLIN2—skin cancer	1.64e-05	0.00131	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.61e-05	0.00128	CbGpPWpGaD
Daunorubicin—TOP2A—Circadian rythm related genes—TP53—skin cancer	1.6e-05	0.00127	CbGpPWpGaD
Daunorubicin—SLC22A2—Neuronal System—BRAF—skin cancer	1.54e-05	0.00123	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	1.54e-05	0.00123	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—CSPG4—skin cancer	1.52e-05	0.00121	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—CSPG4—skin cancer	1.47e-05	0.00117	CbGpPWpGaD
Daunorubicin—TOP2A—Circadian rythm related genes—IL6—skin cancer	1.46e-05	0.00117	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.45e-05	0.00115	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—ENO2—skin cancer	1.37e-05	0.0011	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—CSPG4—skin cancer	1.34e-05	0.00107	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—CSPG4—skin cancer	1.32e-05	0.00106	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.31e-05	0.00104	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—CDKN2A—skin cancer	1.29e-05	0.00103	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.29e-05	0.00103	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—SHH—skin cancer	1.23e-05	0.000984	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—ENO2—skin cancer	1.23e-05	0.000984	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—PLIN2—skin cancer	1.19e-05	0.000949	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—PLIN2—skin cancer	1.12e-05	0.000896	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—ERCC2—skin cancer	1.08e-05	0.000865	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.08e-05	0.000858	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—ENO2—skin cancer	1.03e-05	0.000824	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—TP53—skin cancer	1.03e-05	0.000822	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—FOXO4—skin cancer	1.01e-05	0.000802	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—ENO2—skin cancer	9.99e-06	0.000797	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—CSPG4—skin cancer	9.58e-06	0.000765	CbGpPWpGaD
Daunorubicin—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	9.24e-06	0.000738	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	9.2e-06	0.000735	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—ENO2—skin cancer	9.09e-06	0.000725	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—CSPG4—skin cancer	9.05e-06	0.000722	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—ENO2—skin cancer	8.99e-06	0.000718	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—PLIN2—skin cancer	8.97e-06	0.000716	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.08e-06	0.000645	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—ERCC2—skin cancer	7.98e-06	0.000637	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.81e-06	0.000624	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—CSPG4—skin cancer	7.23e-06	0.000577	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—TP53—skin cancer	7.2e-06	0.000575	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—ERCC2—skin cancer	7.16e-06	0.000572	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—PLIN2—skin cancer	7.16e-06	0.000571	CbGpPWpGaD
Daunorubicin—SLC22A2—Neuronal System—HRAS—skin cancer	7.08e-06	0.000565	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—TERT—skin cancer	6.71e-06	0.000536	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—ENO2—skin cancer	6.51e-06	0.00052	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—PTGS2—skin cancer	6.49e-06	0.000518	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	6.16e-06	0.000492	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—ENO2—skin cancer	6.15e-06	0.000491	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—ERCC2—skin cancer	6e-06	0.000479	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—ERCC2—skin cancer	5.8e-06	0.000463	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—CSPG4—skin cancer	5.77e-06	0.000461	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—PLIN2—skin cancer	5.52e-06	0.000441	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	5.48e-06	0.000437	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—BRAF—skin cancer	5.32e-06	0.000424	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—ERCC2—skin cancer	5.28e-06	0.000421	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—ERCC2—skin cancer	5.22e-06	0.000417	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—ENO2—skin cancer	4.91e-06	0.000392	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.81e-06	0.000384	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—PTGS2—skin cancer	4.79e-06	0.000382	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—CSPG4—skin cancer	4.45e-06	0.000355	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—PTGS2—skin cancer	4.29e-06	0.000343	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—ENO2—skin cancer	3.92e-06	0.000313	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—ERCC2—skin cancer	3.78e-06	0.000302	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—PTGS2—skin cancer	3.6e-06	0.000287	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—ERCC2—skin cancer	3.57e-06	0.000285	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—PTGS2—skin cancer	3.48e-06	0.000278	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—NRAS—skin cancer	3.34e-06	0.000267	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—PTGS2—skin cancer	3.16e-06	0.000253	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—PTGS2—skin cancer	3.13e-06	0.00025	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.07e-06	0.000245	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—ENO2—skin cancer	3.03e-06	0.000242	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—KRAS—skin cancer	2.88e-06	0.00023	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—ERCC2—skin cancer	2.85e-06	0.000228	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—HRAS—skin cancer	2.44e-06	0.000195	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—IL6—skin cancer	2.34e-06	0.000187	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—ERCC2—skin cancer	2.28e-06	0.000182	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—PTGS2—skin cancer	2.27e-06	0.000181	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—PTGS2—skin cancer	2.14e-06	0.000171	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—ERCC2—skin cancer	1.76e-06	0.00014	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—PTGS2—skin cancer	1.71e-06	0.000137	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—PTGS2—skin cancer	1.37e-06	0.000109	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—PTGS2—skin cancer	1.05e-06	8.42e-05	CbGpPWpGaD
